Education
About Us
Working with TipRanks
Follow Us
Standard Biotools Inc (LAB)
:LAB
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.27Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: -0.85%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
Despite the successful realization of cost synergies and a strong balance sheet, the company faced significant revenue declines and market challenges, including reduced instrument sales and potential impacts from NIH funding and tariffs. The growth in consumables and strategic initiatives in proteomics provide optimism, but the current market and economic environment pose challenges.Company Guidance
During the fourth quarter and full year 2024 financial results call, Standard BioTools provided a comprehensive overview of their performance and outlined guidance for 2025. The company reported $46.7 million in revenue for the fourth quarter and $175.1 million for the full year, both reflecting a 9% year-over-year decline. Despite the revenue drop, the company achieved a 33% improvement in adjusted EBITDA compared to 2023, driven by $80 million in cost synergies operationalized through the merger with SomaLogic. Looking forward, Standard BioTools anticipates 2025 organic revenue between $165 million and $175 million, an approximate 3% decline at the midpoint, factoring in anticipated headwinds such as a mid-teens percentage decline in Americas academic revenue due to potential NIH funding cuts. The company maintains a strong balance sheet with nearly $300 million in cash, positioning it to execute strategic plans and fund potential acquisitions. They remain on track to reach adjusted EBITDA breakeven in 2026, even as they navigate macroeconomic challenges and evolving market conditions.Cost Synergies and Operational Improvements
Operationalized $80 million in cost synergies a year ahead of plan, with an additional $10 million in cost reductions. Achieved a 22% year-over-year reduction in non-GAAP operating expenses and a 33% improvement in adjusted EBITDA.
Strong Balance Sheet
Nearly $300 million in cash with substantially no debt, providing flexibility to execute strategic plans and potential acquisitions.
Consumables Growth
Consumables revenue grew 10% in the fourth quarter and 18% for the full year 2024, driven by SomaScan authorized sites and the Illumina early access program.
Proteomics and Illumina Partnership
SomaScan platform is positioned as a leader in plasma proteomics, with a strategic partnership with Illumina, unlocking large-scale protein analysis opportunities. Expecting a significant market opportunity, estimated at $1 billion.
---
LAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $1.17 | $1.04 | -11.11% |
| Oct 30, 2024 | $1.88 | $1.96 | +4.26% |
| Jul 31, 2024 | $2.24 | $1.42 | -36.61% |
| May 08, 2024 | $2.24 | $2.41 | +7.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Standard Biotools Inc (LAB) report earnings?
Standard Biotools Inc (LAB) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Standard Biotools Inc (LAB) earnings time?
Standard Biotools Inc (LAB) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LAB EPS forecast?
LAB EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
---